3. Meadors G. Correspondence to B. Boone, November 1, 1948. In: Papers of the National Heart, Lung, and Blood Institute, Monthly Reports Heart Disease Epidemiology Study Folder.
4. Vague J. Sexual differentiation, a factor affecting the forms of obesity. Pres Med. 1947; 30: 339- 40.
5. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord. 1996; 20: 291- 302.
6. Kissebah AH, Vydelingum N, Murray R. Relation of body fat distribution to metabolic complication of obesity. J Clin Endocrinol Metab 1982; 54: 254- 60.
7. Reaven GM, Banting Conference lecture 1988. Role of insuline resistance in human disease. http://www.ncbi.nlm.nih.gov. [Consulta: 18 noviembre.2010].
8. De Fronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atheroesclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194.
9. Meigs JB, Hu FB, Rifai N. Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus. JAMA 2004; 291: 1978-86.
10. An interview with Gerald Reaven: Syndrome X: the Risks of insuline resistente. http://www.cacrc.ca (Canadian Association of cardiac Rehabilitation- CARC Newsletter Fall 2000).
11. Kaplan JR, Adams MR, Clarkson TB, Manuck SB, Shively CA, Williams JK. Psychosocial Factors, Sex Differences, and Atherosclerosis: Lessons From Animal Models. Psychosomatic Medicine 1996; 58: 598-611.
12. Word Health Organization: definitions, diagnosis and a classification of Diabetes Mellitus and its complications: report of WHO consultation. Geneva. World Health Org., 1999.).
13. Ryder, Elena. Una epidemia global: El Síndrome Metabólico. An Venez Nutr, 2005; 18(1):105-109.
14. Epidemiología, diagnóstico, control, prevención y tratamiento del síndrome metabólico en adultos. Consenso Latinoamericano de la Asociación Latinoamericana de Diabetes, 2007. Disponible en: http://alad-latinoamerica.blogspot.com/2009/12/consenso-latinoamericano de la html.
15. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of WHO consultation. Geneve: WHO; 1999.
16. Eckel RH, Gruñid SM, y Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365:1415-28.
17. Zimmet P, Alberti KG, y Serranos Ríos M. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: Fundamento y resultados. Rev Esp Cardiol. 2005; 58(12): 1371-6.
18. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of insuline resistance (EGIR). Diabet Med. 1999; 16: 442-3.
19. Executive Summary of the Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA.2001; 285:2486-2.
20.Alberti KGMM, Zimmet PZ, Shaw JE. The metabolic syndrome: a new world- wide definition from the International Diabetes Federation consensus. Lancet. 2005; 366: 1059- 62.
21. The IDF consensus worldwide definition of the metabolic syndrome. Internacional Diabetes Federation, 2005. Disponible en:www.idf.org/webdata/docsIDF_Metasyndrome_definition.pdf.
22. Ferreira Montero IJ.Introducción. Rev Esp Cardiol supl. 2005; 5: 1D- 2D.
23. Cordero A, Alegría E, León Montserrat. Prevalencia del síndrome metabólico. Rev Esp Cardiol Supl. 2005; 5: 11D- 5D.
24.Cordero A, Alegria E, Montserrat L. Prevalencia del Síndrome Metabólico. Revista española de cardiología 2006; 5:11-15.
25. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NECP-Defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52:1210-4
26. Ryder E.Una Epidemia Global: El síndrome metabólico. An Venez Nutr. 2005; 18, supl 1.
27. Crepaldi G, Maggi. El Síndrome Metabólico. Contexto histórico. Diabetes Voice. 2006; 51.
28. Instituto de Investigaciones clínicas Dr. Amercico Negrette¨Facultad de Medicina, Universidad de Zulia, Maracaibo, Venezuela. An Venez Nutr.18 (1). Caracas 2005.
29. Duncan GE, Li SM, Zhou XH. Prevalence and trends of a metabolic
syndrome phenotype among US adolescents Diabetes Care 2004; 27:2438-2443
30. Chen w, Srinivasan sr, Berenson gs. Path Analysis of Metabolic
Syndrome Components in black versus white children, adolescents, and
adults: the bogalusa heart study. ann epidemiol 2008;18(2):85-91, pmid: 18191760
31. Bastarrachea RA, Shelley A, Cole A, Comuzzie G. Genómica de la regulación del peso corporal: mecanismos moleculares que predisponen a la obesidad. Med Clin (Barc). 2004; 123: 104- 17.
32. Martín Laclaustra Gimeno, Bergua Martínez Clara, Pascual Calleja Isaac, Casasnovas Lenguas José A. Síndrome metabólico. Concepto y fisiopatología. Rev Esp Cardiol. 2005;5(Supl D):3-10.
33. Maiz G A. El síndrome metabolico y riesgo cardiovascular. Boletín de la Escuela de Medicina 2005; 30 (1).
34. American Association of Clinical Endocrinologist. Code for dismetabolic Syndrome X. Año 2002.
35. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000; 106:453-8.
36. Malik J, Melenovsky V, Wichterle D, [et al.]. Both fenofibrato and atorvastatin improve vascular reactivity in combined hyperlipemia. Cardiovasc Res 2001; 52:290-298.
37. Crook ED. The genetics of human hypertension. Semin Nephrol 2002; 22:27-34.
38. Fruehwald E, Schultes B. Hiperinsulinemia causes activation of the hypo-thalamus-pituitary-adrenal axis in human. Int J Obes Relat Metab Disord. 2001; 1:538-540.
39. Del Río Ligorit A, Ferreira Montero IJ, Casasnovas Lenguas JA, Alegría Ezquerra E, Laclaustra M, León M, et al. Temas de actualidad en cardiología preventiva: el síndrome metabólico. Rev Esp Cardiol supl. 2005; 5: 13 A- 23A.
40. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998; 47: 1643-9.
41. Chobanian AV, Bakris GR, Black HF, Cushman WC, Green LA, Izzo JL, et al. for the National Heart, Lung and Blood institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:2560 -72
42. Cubeddu LX. Insulin resistance and upper – normal glucose levels in hyper-tension: a review. J Human Hypertens 2002; 16(1):52-55.
43 Yudkin JS, Stehouwer CD, Emeis JJ. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999; 19:972-8.
44. García Romero de Tejada G, Escobar Monrreale HF. Hiperandrogenismo en la mujer diabética: rol de la resistencia insulínica y de la hiperinsulinemia. Endocrinol Nutr. 2003; 50:363-368.
45 Martínez de Moretin BE, Rodríguez MC y Martínez JA. Síndrome metabólico, Resistencia a la insulina y metabolismo tisular. Endocrinología y Nutrición 2003; 50(8):326.
46. Zimmet P, Alberti KG, Serrano M. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: fundamento y resultados. Rev Esp Cardiol 2005; 58:1371-76.
47. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-45.
Autor:
Dr. Modesto González Cortiñas
Especialista de 2do Gdo en Medicina Interna.
Prof. Auxiliar de Medicina Interna. ISCMVC.
MCs en Longevidad Satisfactoria
Dr. Ariel Cepero Del Sol
Residente de 2do Año de Medicina General Integral.
| Página siguiente |